X

Trial Profile

A Long-term Study of ADVM-022 in Neovascular (Wet) AMD - OPTIC Extension

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 09 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ixoberogene soroparvovec (Primary)
Indications Wet age-related macular degeneration
Focus Adverse reactions
Acronyms OPTIC-EXT
Sponsors Adverum Biotechnologies

Most Recent Events

04 Nov 2023 According to an Adverum Biotechnologies media release,data from the study were presented at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting in San Francisco, California.
04 Nov 2023 Results presented in the Adverum Biotechnologies Media Release.
03 Nov 2023 Results published in the Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com